ABBOTINDIA vs SUDEEPPHRM: Stock Comparison

Abbott India Limited vs Sudeep Pharma Ltd

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Abbott India Limited is the larger company by market capitalisation. Abbott India Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Sudeep Pharma Ltd shows a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Abbott India Limited and Sudeep Pharma Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, ABBOTINDIA is more favourable on 8 of 13 scored metrics and SUDEEPPHRM on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
ABBOTINDIA is the larger company
₹59,598 Cr vs ₹9,323 Cr
P/E Ratio
ABBOTINDIA has a lower P/E
38.38x vs 53.82x
P/B Ratio
SUDEEPPHRM has a lower P/B
10.54x vs 12.48x
EPS
ABBOTINDIA has higher earnings per share
₹731.52 vs ₹15.3
Dividend Yield
ABBOTINDIA has a higher dividend yield
1.82% vs 0%
Revenue Growth (TTM YoY)
ABBOTINDIA has faster revenue growth
6.5% vs 0%
EPS Growth (TTM YoY)
ABBOTINDIA has faster EPS growth
7.6% vs 0%
Qtr Sales Growth
SUDEEPPHRM has stronger quarterly sales growth
15.7% vs 6.54%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricABBOTINDIASUDEEPPHRM
SectorHealthcare
IndustryPharmaceuticals

Price

MetricABBOTINDIASUDEEPPHRM
Live Price₹28,005₹825.15
Day Change-0.1%1.21%
Volume10,8111.26 L
52-Week High₹35,310₹894.95
52-Week Low₹25,150₹524.05
Distance from 52W High-20.69%-7.8%

Valuation

MetricABBOTINDIASUDEEPPHRM
Market Cap₹59,598 Cr₹9,323 Cr
P/E Ratio38.38x53.82x
P/B Ratio12.48x10.54x
EPS₹731.52₹15.3
Book Value₹2,246.69₹78.2
Dividend Yield1.82%0%

Growth

MetricABBOTINDIASUDEEPPHRM
Revenue Growth (TTM YoY)6.5%0%
EPS Growth (TTM YoY)7.6%0%
Qtr Sales Growth6.54%15.7%
Qtr Profit Growth7.6%10.6%

Profitability & Leverage

MetricABBOTINDIASUDEEPPHRM
ROE34.5%25.2%
ROCE44.9%28.1%
Net Margin22.4%27.14%
Operating Margin27.3%34.6%
Debt to Equity0.04x0.17x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricABBOTINDIASUDEEPPHRM
Promoter Holding74.99%76.15%
FII Holding0.26% 0.08 pp1.81% 0.26 pp
DII Holding8.93% 0.07 pp15.65% 2.46 pp
Public Holding15.81% 0.02 pp6.39% 2.21 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Abbott India Limited and Sudeep Pharma Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.